Overview

Pembrolizumab in Untreated Extensive SCLC

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, two armed, controlled, and randomized phase II trial investigating the activity of pembrolizumab in combination with standard chemotherapy in Extensive Disease (ED)-SCLC.

Phase:

Phase 2

Details

Lead Sponsor:

European Organisation for Research and Treatment of Cancer - EORTC

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Carboplatin
Etoposide
Etoposide phosphate
Pembrolizumab